Table 1.

Demographics and clinical characteristics of COVID-19 IBD patients treated with TNF antagonists, thiopurines or the combination

Characteristic*	TNF antagonist monotherapy n=410	Thiopurine monotherapy n=155	P value†	Combination therapy n=105	P value‡
Mean age, years (SD)	38.5 (16.2)	45.6 (16.0)	<0.001	41.1 (15.0)	0.13
Female, n (%)	194 (47.3)	73 (47.1)	0.82	48 (45.7)	0.67
Race, n (%)
White	338 (82.4)	133 (85.8)	0.34	89 (84.8)	0.57
Asian	0.001	12 (8.8)	<0.001	20 (12.9)	10 (2.4)
Black	35 (8.5)	6 (3.9)	0.06	4 (3.8)	0.10
Ethnicity, n (%)
Hispanic	63 (15.4)	34 (21.9)	0.05	23 (21.9)	0.05
CD, n (%)	292 (71.2)	78 (50.3)	<0.001	66 (62.9)	0.06
UC/IBD-U, n (%)	118 (28.8)	77 (49.7)		39 (37.1)
Disease Aactivity, n (%)
Remission	258 (62.9)	98 (63.3)	0.80	57 (54.3)	0.35
Mild	69 (16.8)	30 (19.4)		17 (16.2)
Moderate/Ssevere, n (%)	72 (17.6)	25 (16.1)		27 (25.7)
Missing/Uunknown, n (%)	6 (1.5)	2 (1.2)		4 (3.8)
Current smoker, n (%)	16 (3.9)	5 (3.2)	0.70	6 (5.7)	0.41
Any comorbidity, n (%)	114 (27.8)	49 (31.6)	0.37	40 (38.1)	0.04
Cardiovascular Ddisease, n (%)	15 (3.7)	13 (8.4)	0.02	11 (10.5)	0.004
BMI ≥30 kg/m2, n (%)	62 (15.1)	23 (14.8)	0.79	25 (23.8)	0.10
Mesalamine/sulfasalazine, n (%)	43 (10.5)	61 (39.4)	<0.001	27 (25.7)	<0.001
Corticosteroid, n (%)	17 (4.1)	16 (10.3)	0.005	16 (15.2)	<0.001
Severe COVID-19, n (%)	9 (2.2)	15 (9.7)	<0.001	10 (9.5)	<0.001
Death from COVID-19 or related complications, n (%)	3 (0.7)	3 (1.9)	0.36	3 (2.9)	0.17

*Percentages and n from each subcategory may not add up to the exact number of total reported cases due to missing values and/or non-mutually exclusive variables.

†P value comparing thiopurine monotherapy with TNF antagonist monotherapy.

‡P value comparing combination therapy with TNF antagonist monotherapy.

BMI, body mass index; CD, Crohn’s disease; IBD-U, IBD unclassified; TNF, tumour necrosis factor.;